Skip to main content

Table 2 Description of the therapeutic indication of the vaccines under study

From: Use of Logistic Regression to Combine Two Causality Criteria for Signal Detection in Vaccine Spontaneous Report Data

Vaccine Therapeutic indication (extracted from on 14 August 2014)
Engerix™ Active immunization against hepatitis B virus infection caused by all known subtypes in non-immune subjects
Havrix™ (adult and pediatric) Active immunization against infections caused by hepatitis A virus
Cervarix™ Vaccine for use from the age of 9 years for the prevention of premalignant genital (cervical, vulvar, and vaginal) lesions and cervical cancer causally related to certain oncogenic human papillomavirus types
Infanrix™ Vaccine indicated for booster vaccination against diphtheria, tetanus, pertussis, and poliomyelitis diseases in individuals from 16 months to 13 years of age inclusive who have previously received primary immunization series against these diseases
Infanrix™ Hib Active immunization against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b disease from the age of 2 months
Rotarix™ Active immunization of infants aged 6–24 weeks for prevention of gastroenteritis due to rotavirus infection
Fluarix™ Prophylaxis of influenza, especially those who run an increased risk of associated complications. Fluarix™ is indicated in adults and children from 6 months of age
Twinrix™ (adult and pediatric) Indicated for individuals who are at risk of both hepatitis A and hepatitis B infection